Brain Tumor Center: Ingo Mellinghoff Named the Evnin Family Chair in Neuro-Oncology

Tuesday, July 1, 2014
Pictured: Ingo Mellinghoff Physician-scientist Ingo Mellinghoff

Physician-scientist Ingo Mellinghoff has been designated the incumbent of the Evnin Family Chair in Neuro-Oncology. Established through the generosity of Dr. Tony Evnin, a general partner of venture capital firm Venrock and a member of Memorial Sloan Kettering’s Boards of Overseers and Managers, the endowed chair is designed to recognize extraordinary excellence, and the faculty members chosen for these honors are among the institution’s most accomplished scholars and physicians.

Dr. Mellinghoff, who runs a research laboratory in Memorial Sloan Kettering’s Human Oncology and Pathogenesis Program and also serves as Vice Chair for Research in the Department of Neurology, focuses his research on the identification and functional characterization of genetic alterations in primary human brain tumors. He also works on the development of novel treatment approaches that target these alterations.

A practicing neuro-oncologist, Dr. Mellinghoff has also led clinical trials involving signal transduction inhibitors.